Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy

Robert L Spicer, A. P. Rocchini, D. C. Crowley, J. Vasiliades, A. Rosenthal

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The acute hemodynamic effects of verapamil were evaluated in nine children with hypertrophic cardiomyopathy. Verapamil, 0.1 mg/kg, was administered as a i.v. bolus over 2 minutes, followed by a 20-minute continuous infusion of 0.007 mg/kg/min. Hemodynamic measurements were obtained at rest in nine patients and at maximal supine bicycle exercise in seven before and 15 minutes after verapamil. At rest, verapamil increased the mean cardiac output from 3.3 ± 0.9 to 3.7 ± 0.9 l/min/m2 (± SD) (p < 0.02) and decreased left ventricular end-diastolic pressure from 19.3 ± 8.1 to 14.5 ± 6.9 mm Hg (p < 0.006). In six patients with resting left ventricular outflow tract obstruction, the systolic pressure gradient decreased from 17.5 ± 7.2 to 5.2 ± 4.5 mm Hg (p < 0.04). Repeat supine bicycle exercise testing after verapamil showed increases in total work performed (1743 ± 1284 to 3168 ± 1643 kg-m, p < 0.006) and maximal cardiac index during exercise (6.5 ± 1.3 to 7.8 ± 1.8 l/min/m2, p < 0.05), and decreases in maximal exercise left ventricular end-diastolic pressure (29.1 ± 10.1 to 19.3 ± 10.4 mm Hg, p < 0.002) and left ventricular systolic outflow tract gradient (31.2 ± 10.5 to 1.75 ± 1.7 mm Hg, p < 0.04). These results suggest that verapamil may be an effective therapeutic agent for the treatment of hypertrophic cardiomyopathy in children.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalUnknown Journal
Volume67
Issue number2
DOIs
StatePublished - Jan 1 1983

Fingerprint

Hypertrophic Cardiomyopathy
Hemodynamics
Verapamil
Exercise
Exercise equipment
Blood Pressure
Ventricular Outflow Obstruction
Pressure gradient
Cardiac Output
Testing
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. / Spicer, Robert L; Rocchini, A. P.; Crowley, D. C.; Vasiliades, J.; Rosenthal, A.

In: Unknown Journal, Vol. 67, No. 2, 01.01.1983, p. 413-420.

Research output: Contribution to journalArticle

Spicer, Robert L ; Rocchini, A. P. ; Crowley, D. C. ; Vasiliades, J. ; Rosenthal, A. / Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. In: Unknown Journal. 1983 ; Vol. 67, No. 2. pp. 413-420.
@article{faddc6015c3b411dbd8266647a94c445,
title = "Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy",
abstract = "The acute hemodynamic effects of verapamil were evaluated in nine children with hypertrophic cardiomyopathy. Verapamil, 0.1 mg/kg, was administered as a i.v. bolus over 2 minutes, followed by a 20-minute continuous infusion of 0.007 mg/kg/min. Hemodynamic measurements were obtained at rest in nine patients and at maximal supine bicycle exercise in seven before and 15 minutes after verapamil. At rest, verapamil increased the mean cardiac output from 3.3 ± 0.9 to 3.7 ± 0.9 l/min/m2 (± SD) (p < 0.02) and decreased left ventricular end-diastolic pressure from 19.3 ± 8.1 to 14.5 ± 6.9 mm Hg (p < 0.006). In six patients with resting left ventricular outflow tract obstruction, the systolic pressure gradient decreased from 17.5 ± 7.2 to 5.2 ± 4.5 mm Hg (p < 0.04). Repeat supine bicycle exercise testing after verapamil showed increases in total work performed (1743 ± 1284 to 3168 ± 1643 kg-m, p < 0.006) and maximal cardiac index during exercise (6.5 ± 1.3 to 7.8 ± 1.8 l/min/m2, p < 0.05), and decreases in maximal exercise left ventricular end-diastolic pressure (29.1 ± 10.1 to 19.3 ± 10.4 mm Hg, p < 0.002) and left ventricular systolic outflow tract gradient (31.2 ± 10.5 to 1.75 ± 1.7 mm Hg, p < 0.04). These results suggest that verapamil may be an effective therapeutic agent for the treatment of hypertrophic cardiomyopathy in children.",
author = "Spicer, {Robert L} and Rocchini, {A. P.} and Crowley, {D. C.} and J. Vasiliades and A. Rosenthal",
year = "1983",
month = "1",
day = "1",
doi = "10.1161/01.CIR.67.2.413",
language = "English (US)",
volume = "67",
pages = "413--420",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy

AU - Spicer, Robert L

AU - Rocchini, A. P.

AU - Crowley, D. C.

AU - Vasiliades, J.

AU - Rosenthal, A.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - The acute hemodynamic effects of verapamil were evaluated in nine children with hypertrophic cardiomyopathy. Verapamil, 0.1 mg/kg, was administered as a i.v. bolus over 2 minutes, followed by a 20-minute continuous infusion of 0.007 mg/kg/min. Hemodynamic measurements were obtained at rest in nine patients and at maximal supine bicycle exercise in seven before and 15 minutes after verapamil. At rest, verapamil increased the mean cardiac output from 3.3 ± 0.9 to 3.7 ± 0.9 l/min/m2 (± SD) (p < 0.02) and decreased left ventricular end-diastolic pressure from 19.3 ± 8.1 to 14.5 ± 6.9 mm Hg (p < 0.006). In six patients with resting left ventricular outflow tract obstruction, the systolic pressure gradient decreased from 17.5 ± 7.2 to 5.2 ± 4.5 mm Hg (p < 0.04). Repeat supine bicycle exercise testing after verapamil showed increases in total work performed (1743 ± 1284 to 3168 ± 1643 kg-m, p < 0.006) and maximal cardiac index during exercise (6.5 ± 1.3 to 7.8 ± 1.8 l/min/m2, p < 0.05), and decreases in maximal exercise left ventricular end-diastolic pressure (29.1 ± 10.1 to 19.3 ± 10.4 mm Hg, p < 0.002) and left ventricular systolic outflow tract gradient (31.2 ± 10.5 to 1.75 ± 1.7 mm Hg, p < 0.04). These results suggest that verapamil may be an effective therapeutic agent for the treatment of hypertrophic cardiomyopathy in children.

AB - The acute hemodynamic effects of verapamil were evaluated in nine children with hypertrophic cardiomyopathy. Verapamil, 0.1 mg/kg, was administered as a i.v. bolus over 2 minutes, followed by a 20-minute continuous infusion of 0.007 mg/kg/min. Hemodynamic measurements were obtained at rest in nine patients and at maximal supine bicycle exercise in seven before and 15 minutes after verapamil. At rest, verapamil increased the mean cardiac output from 3.3 ± 0.9 to 3.7 ± 0.9 l/min/m2 (± SD) (p < 0.02) and decreased left ventricular end-diastolic pressure from 19.3 ± 8.1 to 14.5 ± 6.9 mm Hg (p < 0.006). In six patients with resting left ventricular outflow tract obstruction, the systolic pressure gradient decreased from 17.5 ± 7.2 to 5.2 ± 4.5 mm Hg (p < 0.04). Repeat supine bicycle exercise testing after verapamil showed increases in total work performed (1743 ± 1284 to 3168 ± 1643 kg-m, p < 0.006) and maximal cardiac index during exercise (6.5 ± 1.3 to 7.8 ± 1.8 l/min/m2, p < 0.05), and decreases in maximal exercise left ventricular end-diastolic pressure (29.1 ± 10.1 to 19.3 ± 10.4 mm Hg, p < 0.002) and left ventricular systolic outflow tract gradient (31.2 ± 10.5 to 1.75 ± 1.7 mm Hg, p < 0.04). These results suggest that verapamil may be an effective therapeutic agent for the treatment of hypertrophic cardiomyopathy in children.

UR - http://www.scopus.com/inward/record.url?scp=0020657089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020657089&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.67.2.413

DO - 10.1161/01.CIR.67.2.413

M3 - Article

VL - 67

SP - 413

EP - 420

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

IS - 2

ER -